Semaglutide vs Tirzepatide: How to Choose With Your Provider

Semaglutide targets one hormone pathway (GLP-1); tirzepatide targets two (GLP-1 and GIP). In the head-to-head SURMOUNT-5 trial, tirzepatide produced more weight loss on average, about 20.2% vs 13.7% over 72 weeks. But the right choice depends on your health, tolerance, goals, and budget, and a provider decides that with you. Both are weekly injections.

Compounded medications are prepared by state-licensed compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality.

If you are weighing semaglutide vs tirzepatide, you are asking a smart question, and you are probably close to a decision. Both are once-weekly injections that quiet appetite and food noise. Both help people lose meaningful weight. In 2025, one trial gave the two medications a direct head-to-head test, and the headlines picked a winner. The real answer is more useful than a headline. This guide lays out the honest comparison, what the trial actually found, and how a licensed provider chooses between them with you.

Key takeaways

• Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP).
• In the SURMOUNT-5 trial, tirzepatide produced more weight loss on average, about 20.2% vs 13.7% over 72 weeks.
• A trial average is not a personal prediction. Individual results vary.
• A provider weighs your history, GI tolerance, goals, and budget with you before choosing.
• Both are available as compounded medications, which are not FDA-approved.

Semaglutide vs tirzepatide: the quick comparison

Here is the whole semaglutide vs tirzepatide picture on one screen. Read down each column, then read the sections below for what the numbers mean and how a provider uses them. The table describes the medications. It does not describe your dose, which a provider sets with you.

Those percentages are group averages from a controlled trial. They are a useful benchmark, not a promise. Your results depend on your body, your consistency, clinical guidance, and lifestyle factors.

What did the head-to-head trial actually find?

For years, people compared semaglutide and tirzepatide using separate trials, which is a bit like timing two runners on different tracks. That changed with the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025. It put the two medications against each other directly.

SURMOUNT-5 was an open-label, randomized study of 751 adults with obesity, run over 72 weeks. Each person was titrated to their maximum tolerated dose under supervision. Tirzepatide produced an average weight reduction of about 20.2%, compared with about 13.7% for semaglutide. In real numbers, that was roughly 22.8 kg versus 15.0 kg. According to the American College of Cardiology’s summary of the trial, about 31.6% of the tirzepatide group lost at least a quarter of their body weight, compared with 16.1% on semaglutide.

So on paper, tirzepatide led. That is the honest finding, and it is why most headlines named it. But an average hides the spread. Plenty of people on semaglutide lost more than the average, and plenty on tirzepatide lost less. A trial tells you what happened across a group. It cannot tell you what will happen for you, which is exactly the gap a provider fills.

How does a provider actually choose between them?

This is the part almost every article skips. They show you the trial, then tell you to talk to your provider, without ever saying what that conversation covers. Here is what a licensed provider actually weighs when choosing between semaglutide and tirzepatide with you.

None of these five factors show up in a trial average. That is the point. The best choice is the medication you will tolerate, afford, and take consistently, chosen by a provider who knows your history. You can start that review by checking whether you qualify and completing a short evaluation.

How do the side effects compare?

Both semaglutide and tirzepatide share the same side effect profile, and it is mostly gastrointestinal. Think nausea, diarrhea, constipation, and reflux. For most people, these effects show up early, cluster around dose increases, and ease as the body adjusts. To understand the shared mechanism, see what a GLP-1 is and how tirzepatide works.

Does more weight loss mean more side effects? Not in the way you might expect. In SURMOUNT-5, gastrointestinal side effects that led people to stop treatment were actually a little less common with tirzepatide (about 2.7%) than with semaglutide (about 5.6%). Most side effects in both groups were mild to moderate. Still, tolerance is personal. Two people on the same medication can have very different first months.

A slow, supervised titration is how a provider keeps side effects manageable. Support options, such as FDA-approved Ondansetron ODT for nausea, may be available during titration. If you ever have severe or persistent vomiting, fainting, or severe abdominal pain, that is not a home-management situation. Contact support or seek medical care.

What about compounded semaglutide and tirzepatide?

The brand names in the table, Ozempic, Wegovy, Mounjaro, and Zepbound, are the FDA-approved manufactured products. Compounded semaglutide and tirzepatide are a different category. They contain the same active molecules, but they are prepared by state-licensed compounding pharmacies and are not FDA-approved. That does not mean unregulated. It means a compounding pharmacy prepares them under state and federal pharmacy standards, and the FDA has not reviewed the specific compounded product for safety, efficacy, or quality.

The comparison in this guide still applies at the molecule level. Semaglutide is semaglutide, whether branded or compounded, and the same is true for tirzepatide. A licensed provider decides whether a compounded option is appropriate for you, and no request is approved automatically.

Can you switch from one to the other?

Yes, people do switch between semaglutide and tirzepatide, but it is a provider decision, not a do-it-yourself one. Common reasons to switch include side effects on the first medication, a stall in progress, cost, or supply. What you should never do is stop one and start the other on your own, or stack doses to catch up.

Switching medications usually means starting the new one at a lower dose and building back up, so your body can re-adjust. A provider guides that transition and sets the plan. If your circumstances change, message support rather than changing anything yourself.

Is one worth more than the other?

Value is not the same as the bigger number in a trial. Tirzepatide typically costs more than semaglutide, and the medication that fits your budget is the one you will keep taking. Consistency, not raw potency, is what protects your progress over months and years.

This is where flat, transparent pricing matters. AHC uses flat monthly pricing with no membership fees and no dose-escalation markups, so stepping up your dose does not step up your bill. That removes a quiet pressure other models create, where a higher dose costs more. The right answer to semaglutide vs tirzepatide is rarely the strongest option on paper. It is the one that fits your life, chosen with a provider who explains the trade-offs.

Frequently asked questions

Which is better for weight loss, semaglutide or tirzepatide?

On average, tirzepatide produced more weight loss than semaglutide in the head-to-head SURMOUNT-5 trial, about 20.2% versus 13.7% over 72 weeks. But an average is not a personal result. The better choice for you depends on your health, tolerance, goals, and budget, decided with a provider.

Is tirzepatide stronger than semaglutide?

In trial averages, tirzepatide led to greater weight loss. That reflects its dual action on GLP-1 and GIP receptors, while semaglutide acts on GLP-1 alone. Stronger on average does not mean better for every individual, which is why the choice is provider-guided.

How much more weight do you lose on tirzepatide vs semaglutide?

In SURMOUNT-5, the average difference was about 6.5 percentage points, roughly 20.2% versus 13.7% of body weight over 72 weeks. Individual results varied widely in both groups. Your own results depend on consistency, clinical guidance, and lifestyle factors.

What is the SURMOUNT-5 trial?

SURMOUNT-5 was a 2025 open-label, randomized study of 751 adults with obesity, published in the New England Journal of Medicine. It compared tirzepatide and semaglutide directly over 72 weeks, with each participant titrated to a maximum tolerated dose under supervision.

Can you switch from semaglutide to tirzepatide?

Yes, but only under provider guidance. People switch for tolerance, cost, supply, or a stall in progress. Switching usually means starting the new medication lower and building back up. Never stop one and start the other on your own.

Does tirzepatide have more side effects than semaglutide?

Both share a mainly gastrointestinal side effect profile. In SURMOUNT-5, gastrointestinal effects that led people to stop treatment were slightly less common with tirzepatide than with semaglutide. Most effects in both groups were mild to moderate and eased with titration. Tolerance is individual.

Is compounded tirzepatide the same as compounded semaglutide?

No. They contain different active molecules. Tirzepatide acts on two receptors (GLP-1 and GIP), and semaglutide acts on one (GLP-1). Both are available as compounded medications prepared by state-licensed compounding pharmacies, and neither compounded version is FDA-approved.

Should I start with semaglutide or tirzepatide?

There is no universal starting answer. A provider considers your starting point, GI tolerance, any prior GLP-1 experience, your budget, and your health history. The best first medication is the one you can tolerate, afford, and take consistently every week.

Which has fewer GI side effects?

Both cause similar gastrointestinal effects. In the SURMOUNT-5 trial, fewer people stopped tirzepatide because of gastrointestinal effects than stopped semaglutide, but individual tolerance varies. A slow, supervised titration is the main tool for keeping side effects manageable on either medication.

Are Ozempic and Mounjaro the same as semaglutide and tirzepatide?

Ozempic and Wegovy are brand names for semaglutide. Mounjaro and Zepbound are brand names for tirzepatide. Those are FDA-approved manufactured products. Compounded semaglutide and tirzepatide contain the same molecules but are prepared by compounding pharmacies and are not FDA-approved.

Are compounded semaglutide and tirzepatide FDA-approved?

No. Compounded semaglutide and tirzepatide are prepared by state-licensed compounding pharmacies and are not FDA-approved. The FDA has not reviewed the compounded product for safety, efficacy, or quality. A licensed provider decides whether a compounded option is appropriate for you.

Choose your next step with a provider, not a headline

You do not have to settle the semaglutide vs tirzepatide question alone, and you should not settle it from a headline. A licensed provider can look at your history, your goals, and how your body responds, then recommend the option that actually fits. With AHC, both medications are physician-reviewed, flat-priced with no dose-escalation markups, and shipped to your door. Complete a free evaluation to see which fits you.

Disclaimer

This article is for general education and is not medical advice. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality. Results vary by individual and depend on adherence, clinical guidance, and lifestyle factors. No outcome is guaranteed. Always follow the instructions your provider sends you, and contact AHC support at [email protected] with any questions about your treatment.